Literature DB >> 17591802

Aurora-A overexpression as an early marker of reflux-related columnar mucosa and Barrett's oesophagus.

V Agnese1, D Cabibi, D Calcara, M Terrasi, G Pantuso, E Fiorentino, C Intrivici, G Colucci, F Aragona, N Gebbia, V Bazan, A Russo.   

Abstract

BACKGROUND: The development of oesophageal adenocarcinoma is generally closely associated with the presence of a specialised intestinal-type epithelium such as that found in Barrett's oesophagus (BO). A particular histological condition is when the distal oesophagus showing cardiac and/or fundic mucosa without intestinal metaplasia cannot be defined as 'Barrett's mucosa' [condition that we call 'columnar-lined oesophagus' (CLO)] and up till now, there has been no agreement in literature about the management of this condition. Aurora-A overexpression leads to centrosome amplification, chromosomal instability and aneuploidy in mammalian cells. PATIENTS AND METHODS: A prospective study was carried out on 28 consecutive patients who presented columnar mucosa above the gastro-oesophageal junction (GOJ) at endoscopy. As controls, two more biopsies were obtained, one on the normal-appearing squamous oesophagus above the GOJ, as far as possible from the columnar mucosa (controls A), and one taken 1 cm below the GOJ (controls B). The Aurora-A and p53 expression levels were analysed respectively by Quantitative Real Time PCR and immunohistochemistry.
RESULTS: Twelve patients were affected by BO (43%) while the other 16 patients (57%) had a CLO. Nine of 28 (32%) cases were focally positive for p53 immunostaining. All the BO/CLO samples were positive for the Aurora-A transcript with regard to controls. Furthermore, 13 of 28 (46%) cases showed overexpression (above the median for the whole group).
CONCLUSION: Due to the low number of cases, we are not at present able to state that statistically significant quantitative differences in Aurora-A messenger RNA expression exist between CLO and BO cases with and without dysplasia and p53-positive immunostaining. Further studies on a larger number of cases with a follow-up period are necessary in order to establish the risk of progression and the correct management of these subjects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17591802     DOI: 10.1093/annonc/mdm237

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  5 in total

1.  Copy-number increase of AURKA in gastric cancers in a Chinese population: a correlation with tumor progression.

Authors:  Zhengyu Fang; Yi Xiong; Jiana Li; Li Liu; Manhui Li; Chao Zhang; Wei Zhang; Jun Wan
Journal:  Med Oncol       Date:  2010-06-29       Impact factor: 3.064

Review 2.  Targeting the cell cycle in esophageal adenocarcinoma: an adjunct to anticancer treatment.

Authors:  Martyn Dibb; Yeng S Ang
Journal:  World J Gastroenterol       Date:  2011-04-28       Impact factor: 5.742

3.  Occurrence of multipolar mitoses and association with Aurora-A/-B kinases and p53 mutations in aneuploid esophageal carcinoma cells.

Authors:  Christiane D Fichter; Corinna Herz; Claudia Münch; Oliver G Opitz; Martin Werner; Silke Lassmann
Journal:  BMC Cell Biol       Date:  2011-04-06       Impact factor: 4.241

4.  Immunohistochemical/histochemical double staining method in the study of the columnar metaplasia of the oesophagus.

Authors:  D Cabibi; A G Giannone; C Mascarella; C Guarnotta; M Castiglia; G Pantuso; E Fiorentino
Journal:  Eur J Histochem       Date:  2014-03-05       Impact factor: 3.188

5.  Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus.

Authors:  Daniela Cabibi; Stefano Caruso; Viviana Bazan; Marta Castiglia; Giuseppe Bronte; Sabrina Ingrao; Daniele Fanale; Antonina Cangemi; Valentina Calò; Angela Listì; Lorena Incorvaia; Antonio Galvano; Gianni Pantuso; Eugenio Fiorentino; Sergio Castorina; Antonio Russo
Journal:  Oncotarget       Date:  2016-07-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.